Supporting Information

Pharmaceutical Cocrystals of Naringenin with Improved Dissolution Performance

Chun Luo [a,b], Wendong Liang [a], Xin Chen [b], Jianming Wang [c], Zongwu Deng [b], Hailu Zhang [b,*]

[a] *College of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, People's Republic of China.*

[b] *Laboratory of Magnetic Resonance Spectroscopy and Imaging, Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, Suzhou 215123, People's Republic of China.*

[c] *Crystal Pharmatech, Suzhou Industrial Park, Suzhou 215123, People's Republic of China.*

[*]Corresponding author:

Tel: +86-512-62872713, Fax: +86-512-62603079, E-mail: hlzhang2008@sinano.ac.cn.



Fig. S1. ^{1}H NMR spectra of (a) NAR-INM, (b) NAR-PCA, (c) NAR-BTN form A, (d) NAR-BTN form B. RI: relative integrals of the ^{1}H signals.



Fig. S2. Powder XRD patterns of experimental material and simulated racemic crystal form (CCDC: 1143928) of NAR.



Fig. S3. Powder XRD patterns of NAR-BTN form A before and after heated (155 °C, 5 minutes).



Fig. S4. Powder XRD patterns of NAR-INM, NAR-PCA, NAR-BTN form A and NAR-BTN form B after dissolution experiments.